An international trial of deferiprone in patients with parkinson’s disease

Recruitment & Eligibility

Status: ot Recruiting

Sex: Not specified

Target Recruitment: 140

Inclusion Criteria

1. Male or female aged =18 to < 80 years

2. Body weight =60 kg but =100 kg

3. Parkinson’s disease diagnosed according to Gibb’s criteria (1988) and based on the presence of at least two of the three cardinal features of the disease (rest tremor, bradykinesia, and rigidity). If rest tremor is not present, patient must have unilateral onset of symptoms.

4. Absolute neutrophil count (ANC) =1.5 x 109/L (=1.0 x 109/L for Black population) at screening

5. On a stable dose for at least 3 months prior to the screening visit of any of the following treatments at an L-dopa equivalent daily dose of up to 600 mg:
o Dopaminergic agonist alone
o L-dopa alone
o Combination therapy with dopaminergic agonist and L-dopa
o Rasagiline
o At an early stage of the disease, without motor fluctuations and/or L-dopa–induced dyskinesia
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 90

Exclusion Criteria

1. Diagnosis of Parkinson’s disease more than 3 years prior to screening visit

2. Hoehn and Yahr stage = 3 in the Off” state, indicating the need for walking assistance in the absence of treatment

3. Atypical or secondary Parkinsonism without dopa-sensitivity (e.g., vascular parkinsonism, supranuclear palsy, multisystem atrophy)

4. Progressing Axis I psychiatric disorders (psychosis, hallucinations, compulsive disorders, substance addiction, bipolar disorder, severe depression, anxiety) as assessed in a semi-structured interview in accordance with the Diagnostic and Statistical Manual of Mental Disorders

5. Not stabilized in terms of the current antiparkinsonian therapeutic regimen: already requires dose adaptation and/or is likely to require any change in dopamine therapy over the duration of the trial

6. Current treatment with bromocriptine

7. Current treatment with any antiparkinsonian drug other than those listed in the inclusion criteria

8. Current treatment with coenzyme Q10 or idebenone. (Patients who are on these medications but stop taking them at least 2 weeks prior to baseline may be enrolled.)

9. Current use of a Deep Brain Stimulation (DBS) system. (Patients who previously had a DBS system but have had it removed may be enrolled.)

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials